Cargando…

69: COMPARING THE OUTCOMES OF GIVING TOCILIZUMAB THEN HEMOPERFUSION, HEMOPERFUSION THEN TOCILIZUMAB, AND NO INTERVENTION IN CRITICAL SARS-COV-2 PNEUMONIA PATIENTS IN MAKATI MEDICAL CENTER

Detalles Bibliográficos
Autores principales:	Macatangay, M.V.R., Buensalido, J.A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Poster Session 2
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762126/ http://dx.doi.org/10.1016/S2213-7165(22)00348-4

Ejemplares similares

Endotoxin removal by hemoperfusion in septic shock
por: Adamik, B, et al.
Publicado: (2011)

Hemoperfusion in the intensive care unit
por: Ricci, Zaccaria, et al.
Publicado: (2022)

Efficacy of the CTR-001 direct hemoperfusion adsorption column in sepsis
por: Suzuki, Y, et al.
Publicado: (2008)

More effective use of polymyxin-B hemoperfusion for nonoperation cases
por: Yahata, M, et al.
Publicado: (2014)

563. Tocilizumab in the Treatment of Critical COVID-19 Pneumonia
por: Fisher, Matthew, et al.
Publicado: (2020)

Endotoxin activity assay and polymyxin B hemoperfusion use in a cohort of critically ill patients
por: Cutuli, SL, et al.
Publicado: (2014)

Prognostic comparison of goal-oriented hemoperfusion and routine hemoperfusion combined with continuous venovenous hemofiltration for paraquat poisoning
por: Zhao, Xuming, et al.
Publicado: (2017)

Treatment of Methaqualone overdose with resin hemoperfusion.
por: Baggish, D., et al.
Publicado: (1981)

Hemoperfusion: technical aspects and state of the art
por: Ronco, Claudio, et al.
Publicado: (2022)

Polymyxin B-direct hemoperfusion therapy contributes to oxygen delivery in septic patients
por: Yaguchi, A, et al.
Publicado: (2012)

Physiological response to superantigen-adsorbing hemoperfusion in toxin-concentration-controlled septic swine
por: Ikeda, T, et al.
Publicado: (2006)

Polymyxin B-immobilized fiber hemoperfusion therapy improves sepsis-related immunosuppression
por: Kimura, A, et al.
Publicado: (2014)

Polymyxin B hemoperfusion in high endotoxin activity level septic shock patients
por: Monti, G, et al.
Publicado: (2008)

The effect of endotoxin adsorber hemoperfusion on microcirculation in patients with severe sepsis and septic shock
por: Yeh, Y-C, et al.
Publicado: (2015)

Comparison between Kidney and Hemoperfusion for Paraquat Elimination
por: Kang, Moon-Soo, et al.
Publicado: (2009)

Polymyxin B hemoperfusion: a mechanistic perspective
por: Ronco, Claudio, et al.
Publicado: (2014)

Charcoal Hemoperfusion in Calcium Channel Antagonist Poisoning
por: Kocoğlu Barlas, Ülkem, et al.
Publicado: (2023)

Polymyxin B-direct hemoperfusion therapy improves mean arterial pressure in septic shock
por: Yokota, Mari, et al.
Publicado: (2013)

Beneficial effects of early hemoperfusion with a polymyxin B fibre column on septic shock
por: Takeyama, N, et al.
Publicado: (2009)

Effect of endotoxin absorption by polymixin B hemoperfusion in dialysis-requiring acute kidney injury
por: Iwagami, M, et al.
Publicado: (2015)

553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
por: Leonard, Michael, et al.
Publicado: (2020)

Comparison of Combined Hemodialysis and Hemoperfusion with Hemoperfusion Alone in 106 Patients with Diabetic Ketoacidosis and Acute Renal Failure: A Retrospective Study from a Single Center in China
por: Wang, Guixia, et al.
Publicado: (2021)

Polymyxin B-direct hemoperfusion therapy could contribute to hemodynamics and outcomes in emergency surgical patients
por: Yokota, M, et al.
Publicado: (2012)

Re-evaluation of direct hemoperfusion with polymyxin-B immobilized fiber for severe sepsis and septic shock
por: Matsuo, SM, et al.
Publicado: (2011)

Oxygen metabolism as an indicator in criteria for hemoperfusion using a polymyxin-B immobilized column introduction
por: Kushi, H, et al.
Publicado: (2005)

Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors
por: Cantaluppi, Vincenzo, et al.
Publicado: (2008)

Combined Hemoperfusion and Hemodialysis Treatment of Poisoning with Cholinesterase Inhibitors
por: Durakovic, Zijad
Publicado: (1993)

Prevalence of Empiric Antibacterial Therapy, Community-Acquired Bacterial Superinfection, and Antibiotic-Associated Adverse Reactions among Patients with COVID-19 Pneumonia Admitted in Makati Medical Center from March 2020 to March 2021
por: Galang – De Leon, Waiva Ann M., et al.
Publicado: (2022)

WCN23-0270 ASSOCIATION OF HEMOPERFUSION DISEASE PROGRESSION AMONG PATIENTS WITH SEVERE-TO-CRITICAL COVID-19
por: VICENCIO, M.R., et al.
Publicado: (2023)

Early Hemoperfusion May Improve Survival of Severely Paraquat-Poisoned Patients
por: Hsu, Ching-Wei, et al.
Publicado: (2012)

Effectiveness of polymyxin B hemoperfusion in acute exacerbation of interstitial pneumonia: a retrospective analysis
por: Lee, Song-I
Publicado: (2021)

Does hemoperfusion in combination with other treatments reduce the mortality of patients with paraquat poisoning more than hemoperfusion alone: A systematic review with meta-analysis
por: Nasr Isfahani, Sheida, et al.
Publicado: (2019)

Polymyxin B-immobilized fiber column hemoperfusion has the ability of endotoxin removal during 24 hours
por: Mitaka, C, et al.
Publicado: (2012)

Catecholamine index is a simple and useful marker for bacteremic patients treated by polymyxin B hemoperfusion therapy
por: Isa, Y, et al.
Publicado: (2011)

Hemoperfusion with an immobilized polymyxin B fiber column improves gastric mucosal pH with sepsis patients
por: Kushi, H, et al.
Publicado: (2006)

Polymyxin B Hemoperfusion in Pediatric Septic Shock: Single-Center Observational Case Series
por: Saetang, Patcharin, et al.
Publicado: (2022)

Hemoperfusion in patients with severe COVID-19 respiratory failure, lifesaving or not?
por: Abbasi, Saeed, et al.
Publicado: (2021)

Colchicine poisoning treated with hemoperfusion and hemodialysis: A case report
por: Ramezani, Maral, et al.
Publicado: (2022)

Pharmacokinetics of immunosuppressive agents during hemoperfusion in a sheep model
por: Leber, Bettina, et al.
Publicado: (2023)

The development of immunosorbents for the treatment of systemic lupus erythematosus via hemoperfusion
por: Yu, Yameng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_173n4ubf8jhbi22u28215in02k